{"product_id":"hrtx-bcg-matrix","title":"(HRTX) Heron Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Heron Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo classic star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. ends 2025 with no classic \"star\" because none of its products clearly combines dominant share and fast growth. The mix is still concentrated in a few specialty hospital brands, with APONVIE and ZYNRELEF the closest growth candidates, but not yet clear BCG leaders. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPONVIE 25 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPONVIE 25 mg is Heron Therapeutics, Inc.'s aprepitant injection for postoperative nausea and vomiting, launched in 2022. It sits in a growing perioperative market where PONV can affect up to 30% of surgical patients, so demand is real. Share is still being built, which makes APONVIE a potential Star, not a mature leader yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZYNRELEF dual-acting analgesic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZYNRELEF pairs bupivacaine with meloxicam in one fixed-dose, dual-acting shot, so it fits a Star in Heron Therapeutics, Inc. BCG matrix because it targets opioid-sparing postsurgical pain in a large, durable market. Adoption is still building across hospitals and ambulatory surgery centers, which keeps growth potential high. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiochronomer platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiochronomer is Heron Therapeutics, Inc.’s controlled-release core platform, and it powers long-acting injectables designed to release medicine over days to weeks after one dose. It is a growth engine because it enables new products and life-cycle extensions, but it is not a separate, high-share revenue unit in Heron Therapeutics, Inc.’s reporting. In BCG Matrix terms, it fits best as a strategic enabler with upside, not a cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore tech, not standalone sales\u003c\/li\u003e\n\u003cli\u003eSupports days-to-weeks dosing\u003c\/li\u003e\n\u003cli\u003eGrowth driver with low share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePerioperative hospital channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.'s perioperative hospital channel is the stronger Stars segment in its BCG mix: it targets nausea prevention and pain control, and it benefits from the shift to outpatient surgery plus opioid-sparing care. U.S. ambulatory surgery accounts for more than 60% of surgeries, so demand can scale faster than the legacy oncology antiemetic base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutpatient care supports faster channel growth.\u003c\/li\u003e\n\u003cli\u003ePain and nausea fit opioid-reduction trends.\u003c\/li\u003e\n\u003cli\u003ePerioperative demand beats legacy oncology growth.\u003c\/li\u003e\n\u003cli\u003eChannel can drive better margin mix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron’s 2025\/2026 Growth Bets: APONVIE and ZYNRELEF Lead the Way\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. has no true Stars in 2025\/2026, but APONVIE and ZYNRELEF are the closest growth bets. APONVIE targets a PONV market that affects up to 30% of surgical patients, while ZYNRELEF rides opioid-sparing pain care in a U.S. outpatient surgery base that handles over 60% of procedures.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar fit\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPONVIE\u003c\/td\u003e\n\u003ctd\u003ePotential\u003c\/td\u003e\n\u003ctd\u003eLaunched 2022; PONV up to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZYNRELEF\u003c\/td\u003e\n\u003ctd\u003ePotential\u003c\/td\u003e\n\u003ctd\u003eOpioid-sparing pain; outpatient \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHeron Therapeutics’ BCG Matrix maps its product portfolio into Stars, Cash Cows, Question Marks, and Dogs for strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix for Heron Therapeutics as a pain point reliever, with a clean, C-level-ready view of each business unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Heron Therapeutics, Inc., making key assumptions easier to verify, defend, and update for better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCINVANTI 130 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCINVANTI 130 mg is Heron Therapeutics, Inc.'s most established commercial brand and the clearest recurring cash generator in its portfolio. As an IV aprepitant used to prevent chemotherapy-induced nausea and vomiting, it anchors steady hospital and oncology demand, while Heron also reports ZYNRELEF as a newer growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNK1 antiemetic franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.'s NK1 antiemetic franchise, led by aprepitant products, holds an entrenched spot in supportive oncology care because antiemetic prophylaxis is used with each chemotherapy cycle. That makes demand repeatable and less volatile than new perioperative launches. It is a mature cash cow, but I can’t verify 2025\/2026 revenue or share data from live filings here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2017 FDA approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCINVANTI has been on the market since its 2017 FDA approval, so it is Heron Therapeutics, Inc.'s most mature branded asset. That older age usually means lower launch spending and steadier cash flow than newer products. In BCG terms, this maturity fits a Cash Cow profile because the brand can keep generating revenue without heavy growth investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital formulary base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCINVANTI is already embedded in hospital and infusion-center formularies, so the value now comes from repeat ordering, not heavy launch spend. That makes the hospital base a Cash Cow: access stays sticky, buying is recurring, and cash flow is more predictable than in a push-growth phase. For Heron Therapeutics, Inc., the key is defending formulary slots and refill volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary access drives repeat use\u003c\/li\u003e\n\u003cli\u003eLower spend, steadier orders\u003c\/li\u003e\n\u003cli\u003eCash flow becomes more predictable\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology supportive care revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron's oncology antiemetic sales are its most durable revenue stream because hospitals and clinics reorder supportive care products again and again. Unlike pipeline assets, these medicines are used in routine treatment cycles, so the segment fits the \"cash cow\" label in a BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eRepeat use supports stable demand.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLower risk than pipeline-driven bets.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBest fit for cash generation.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCINVANTI: Heron’s recurring cash generator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCINVANTI, approved in 2017, is Heron Therapeutics, Inc.'s clearest Cash Cow because antiemetic use repeats with each chemotherapy cycle, supporting steady hospital reorder volume. Its value is not fast growth; it is durable, formulary-locked cash flow with lower launch spend. ZYNRELEF is newer, so the mature oncology antiemetic base still does the heavy cash work.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow asset\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eCINVANTI\u003c\/td\u003e\n\u003ctd\u003eFDA approved 2017\u003c\/td\u003e\n\u003ctd\u003eRecurring cash generator\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eHeron Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Heron Therapeutics, Inc. BCG Matrix document you’ll receive after purchase. No demo pages or placeholder content—just the same fully formatted file. Once purchased, it’s ready for immediate use in strategy, analysis, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUSTOL 10 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSUSTOL 10 mg is Heron Therapeutics, Inc.'s extended-release granisetron injection, approved in 2016 for chemotherapy-induced nausea and vomiting. By end-2025, it looks like the weakest commercial brand in the portfolio, with little visible growth versus the newer pain and antiemetic products. In BCG terms, it fits a \"Dog\": low share, low momentum, and limited strategic upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5-HT3 crowded market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGranisetron sits in a crowded 5-HT3 antiemetic class with many low-cost rivals, so Heron Therapeutics, Inc. has limited room to lift share. Older 5-HT3 drugs face pressure from familiar options like ondansetron and palonosetron, which keeps pricing power weak. In BCG terms, this is a Dog: low growth, weak differentiation, and modest return potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy A.P. Pharma asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSUSTOL is a legacy A.P. Pharma asset, not Heron Therapeutics, Inc.'s main growth engine anymore. In Heron Therapeutics, Inc.'s BCG view, slow-moving legacy products with limited demand and low strategic fit belong in \"Dogs.\" That makes SUSTOL a weak-momentum asset, better for harvest or run-off than fresh investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow adoption profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSUSTOL has not turned into a must-have drug, so Heron Therapeutics still fits a Dog on low adoption and weak growth. Hospital and oncology buyers have had cheaper, entrenched substitutes for years, and that keeps switch rates low. In BCG terms, a small share in a slow market is classic Dog behavior.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, low growth\u003c\/li\u003e\n\u003cli\u003eSubstitutes limit uptake\u003c\/li\u003e\n\u003cli\u003eNo dominant market position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMinimal strategic pull\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSUSTOL has minimal strategic pull in Heron Therapeutics, Inc.'s portfolio because the Company has centered growth on CINVANTI, APONVIE, and ZYNRELEF. SUSTOL looks more like a maintenance asset than a capital sink, since companies rarely pour money into products with weak upside.\u003c\/p\u003e\n\u003cp\u003eThat makes it a cash trap, not a growth driver, especially when R\u0026amp;D and sales spend must support higher-return brands. In FY2025, Heron’s strategy still pointed to the newer, larger-opportunity products, with SUSTOL outside the main expansion story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSUSTOL is not the main growth focus.\u003c\/li\u003e\n\u003cli\u003eCINVANTI, APONVIE, ZYNRELEF lead strategy.\u003c\/li\u003e\n\u003cli\u003eLow upside limits capital allocation.\u003c\/li\u003e\n\u003cli\u003eMore likely cash drain than catalyst.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUSTOL: Heron’s Clear Dog and Harvest Asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSUSTOL is Heron Therapeutics, Inc.'s clearest Dog: a legacy antiemetic in a crowded 5-HT3 class, with no separate FY2025 sales disclosed and little visible growth. Heron Therapeutics, Inc. now focuses capital on CINVANTI, APONVIE, and ZYNRELEF, so SUSTOL looks more like a harvest asset than a growth driver.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eSUSTOL\u003c\/td\u003e\n\u003ctd\u003eNo separate sales disclosed\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPONVIE 2022 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPONVIE, launched in 2022, is still early in its commercial life and sits in Heron Therapeutics, Inc.'s Question Mark bucket. It targets postoperative nausea and vomiting, a perioperative need that affects about 30% to 40% of all surgical patients and up to 80% of high-risk patients. To move toward Star status, APONVIE needs faster share gains, stronger hospital adoption, and better repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZYNRELEF 2021 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZYNRELEF, launched in 2021, is Heron Therapeutics, Inc.’s newer non-opioid post-surgical pain product, and it fits the question mark box because demand can still expand fast, but share remains limited. Heron said ZYNRELEF generated $26.6 million in 2024 net product sales, up from $20.8 million in 2023, showing early traction but not scale yet. The pain-control market is large, so wider hospital and surgeon adoption could drive strong growth, but it still needs broader use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHTX-034 Phase Ib\/II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHTX-034 is Heron Therapeutics, Inc.'s next-generation postoperative pain candidate and fits the BCG Question Mark bucket because it is still in Phase Ib\/II. That stage means the asset is early and not yet de-risked, so the upside is high if efficacy and safety hold, but the failure risk is also high. For Heron Therapeutics, Inc., HTX-034’s value will depend on moving from Phase 1\/2 data to later-stage proof, where clinical and commercial odds improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePostoperative pain market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe non-opioid postsurgical pain market is growing as hospitals and ambulatory surgery centers shift toward opioid-sparing care; U.S. ambulatory surgery alone handles more than 50 million procedures a year. Heron Therapeutics, Inc. has a real opening with ZYNRELEF, but in a BCG Matrix this still looks like a Question Mark because share is not yet dominant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003e\u003c\/ul\u003e\n\u003cp\u003eThat means the upside is tied to faster adoption, better payer access, and stronger surgeon pull-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. still needs new labels to broaden use beyond current surgeries and care settings; that makes these assets question marks in the BCG Matrix. If adoption is fast, each new indication can lift share quickly, but the upside is still unproven until surgeons and hospitals switch in volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth needs more procedures and sites\u003c\/li\u003e\n\u003cli\u003eAdoption can drive share gains fast\u003c\/li\u003e\n\u003cli\u003eUntil uptake proves out, stay cautious\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron’s Question Marks Could Turn into Growth Winners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.’s Question Marks are APONVIE, ZYNRELEF, and HTX-034: each has growth potential, but share is still early or unproven. ZYNRELEF posted $26.6 million in 2024 net product sales, up from $20.8 million in 2023, while APONVIE and HTX-034 still need broader uptake and later-stage proof. If hospital adoption and payer access improve, these assets can gain share fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZYNRELEF\u003c\/td\u003e\n\u003ctd\u003e$26.6M sales\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPONVIE\u003c\/td\u003e\n\u003ctd\u003eEarly launch\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTX-034\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\/II\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234590433545,"sku":"hrtx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/hrtx-bcg-matrix.webp?v=1785721178","url":"https:\/\/dcfanalyst.com\/products\/hrtx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}